Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
-8.38%
$6.77
0% positive prob.
5-Day Prediction
-12.33%
$6.47
0% positive prob.
20-Day Prediction
-6.81%
$6.88
0% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q3 2026 | SELL | -8.38% | -12.33% | -6.81% | 100.0% | Pending |
| Q2 2026 | SELL | -8.39% | -12.36% | -6.84% | 99.9% | Pending |
| Q1 2026 | SELL | -7.34% | -11.48% | -5.84% | 100.0% | -23.82% |
| Q4 2025 | SELL | -6.72% | -10.09% | -4.97% | 89.2% | -21.25% |
| Q3 2025 | SELL | -6.12% | -9.92% | -3.43% | 99.9% | -18.85% |
SEC 8-K filings with transcript text
Nov 13, 2026 · 100% conf.
1D
-8.38%
$6.77
5D
-12.33%
$6.47
20D
-6.81%
$6.88
3 ex992transcript.htm
Document
Exhibit 99.2
OptimizeRx Corporation
Third Quarter Fiscal 2026 Earnings Conference Call
November 11, 2026
Stephen Silvestro, Chief Executive Officer
Edward Stelmakh, Chief Financial and Strategy Officer
Andy D'Silva, Chief Business Officer
Heather Favazza, SVP, Corporate Controller
Marion Odence-Ford, Chief Legal & Administrative Officer
Dustin Scaringe, William Blair
Richard Baldry, ROTH Capital Partners
Josh Nichols, B. Riley Securities
Eric Martinuzzi, Lake Street Capital Markets
David Grossman, Stifel
1
Good afternoon everyone, and thank you for joining OptimizeRx's Third Quarter Fiscal 2026 Earnings Conference Call.
With us today is Chief Executive Officer, Stephen Silvestro. He is joined by Chief Financial & Strategy Officer, Edward Stelmakh; Chief Legal & Administrative Officer, Marion Odence-Ford; Chief Business Officer, Andy D'Silva; and Corporate Controller, Heather Favazza.
At the conclusion of today's call, I will provide some important cautions regarding the forward-looking statements made by Management during today's call.
The Company will also discuss certain non-GAAP financial measures that it believes are useful in evaluating operating performance. A reconciliation of these non-GAAP measures can be found in today's earnings release as well as in the Investor Relations section of the Company's website.
I would also like to remind everybody that today's call is being recorded and will be available for replay on the Investor Relations section of the Company's website.
With that, I would like to turn the call over to OptimizeRx Chief Executive Officer Stephen Silvestro. Mr. Silvestro?
Stephen Silvestro
Thank you, Operator, and good afternoon, everyone.
Thank you for joining our third quarter 2026 earnings call.
We are pleased to report third quarter revenue of $21.6 million and Adjusted EBITDA of $6.3 million, both of which exceeded consensus expectations. While revenue came in modestly ahead of expectations, our Adjusted EBITDA performance was again particularly strong, reflecting our continued gross margin strength and the benefits of our disciplined approach to cost management.
Importantly, our bottom line performance reflects the structural improvements we have made to our operating model, including the cost-reduction initiative completed during the first half of the year. These actions have allowed us to operate more efficiently while continuing to invest in the technologies, products, and commercial capabilities we believe will drive long-term growth.
Although the broader pharmaceutical marketing environment remains dynamic, we believe our third quarter performance demonstrates the underlying profitability and operating leverage of our business. At the same time, we recognize that our top line performance has not yet reflected the full potential of investments we've made in our platform.
Contracted revenue for 2026 continues to track approximately 20% below the comparable prior-year. As a result, we have a larger amount of revenue to secure and recognize during the fourth quarter to achieve our previously issued guidance.
ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.
1-888-562-0262 1-604-929-1352 https://viavid.com/
2
Given this backdrop, we are updating the full-year 2026 revenue guidance to a range of $87 million to $93 million, while maintaining our Adjusted EBITDA guidance of $21 to $25 million. This revision reflects expected timing of customer spending decisions and the increased amount of business that would need to convert and be recognized before year-end to achieve our previous revenue expectations.
We remain encouraged by the sustainable progress we're making across our business, including a very encouraging start to 2027. We are seeing expanded opportunities within key accounts, indications of pent-up demand as customers ramp up the 2027 RFP season, and growing commercial opportunities associated with our programmatic distribution capabilities.
We are also pleased to report that one of our previously displaced top five clients has returned and begun to re-invest in new solutions with OptimizeRx.
As you may recall, this customer represented a meaningful portion of our revenue in 2025 but had not generated revenue during the first three quarters of 2026. We are now pleased to report that we have begun generating revenue from this customer during the fourth quarter. While spending has not yet returned to historical levels, we view this as a positive development and an encouraging indication of renewed customer engagement and interest, and contribut
Aug 12, 2026 · 100% conf.
1D
-8.39%
$6.45
Act: +24.72%
5D
-12.36%
$6.17
20D
-6.84%
$6.56
6 ex992leadershipappointment.htm
Document
OptimizeRx Announces Finance Leadership Appointments to Support the Next Phase of Growth
The Company Names Andy D’Silva as the next Chief Financial Officer and Heather Favazza as Chief Accounting Officer effective January 1, 2027.
Planned Transition Reflects Strong Succession Planning and Deep Leadership Bench
WALTHAM, MA. – August 12, 2026 – OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading healthcare technology company enabling life sciences organizations to deliver smarter, more personalized engagement across the healthcare ecosystem, today announced a finance leadership transition that reflects the Company’s disciplined succession planning, deep leadership bench, and confidence in its long-term strategy.
The Company’s Board of Directors has appointed Andy D’Silva to succeed Ed Stelmakh as Chief Financial Officer, effective January 1, 2027. The Board has also appointed Heather Favazza as Chief Accounting Officer, effective January 1, 2027.
To enable a seamless leadership changeover, Stelmakh will continue serving as Chief Financial & Strategy Officer through December 31, 2026. During this period, he will work closely with D’Silva and Favazza to ensure an orderly transfer of responsibilities and continuity of execution. Stelmakh will stay on as a Strategic Advisor through the end of 2027 to ensure a smooth transition.
Over the past five years, Stelmakh helped transform OptimizeRx’s financial foundation and position the Company for its next phase of growth. Under his leadership, the Company significantly expanded gross and operating margins, strengthened operating discipline, refinanced its debt to materially improve its cost of capital, completed the acquisition and successful integration of Medicx, streamlined the portfolio through the divestiture of non-core assets, and built a high-performing finance and strategy organization capable of supporting the Company’s long-term strategic objectives.
Stelmakh also established a culture of disciplined capital allocation, operational excellence, and financial rigor that continues to strengthen OptimizeRx’s ability to create sustainable shareholder value. Equally important, he prioritized the development of outstanding leaders and built a finance organization with the depth, capabilities, and succession readiness to support the Company’s continued growth.
“Ed has been an exceptional partner to me, our Board, and our executive leadership team,” Silvestro said. “His guidance has strengthened our financial foundation, sharpened our strategic execution, and helped build an outstanding finance organization. Perhaps his most enduring contribution is the talented team he has developed, which gives us confidence in this leadership change.”
“Andy has most recently served as Chief Business Officer and has worked closely with the executive leadership team and the Board on the Company’s financial strategy, capital allocation, investor relations, corporate development, and long-range planning,” said Silvestro. “His work has been vital to the strong financial foundation we have established, which makes him well-positioned to step into this new role.”
“Heather has been the Company’s Corporate Controller for the past eight years and has consistently demonstrated strong leadership, technical expertise, and an unwavering commitment to excellence,” Silvestro added. “She has been instrumental in strengthening accounting operations, financial reporting, internal controls, compliance, and the Company’s finance infrastructure and is well prepared to serve as our Chief Accounting Officer.”
Today’s announcement reflects years of thoughtful succession planning by the Company and depth of talent across our finance organization. The Company’s financial and growth strategy remains unchanged. OptimizeRx is well-positioned to capitalize on the significant opportunities ahead and to create long-term value for our shareholders.
About OptimizeRx
OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between healthcare professionals (HCP) and direct-to-consumer (DTC) strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.
Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and cr
May 12, 2026 · 100% conf.
1D
-7.34%
$5.87
Act: -22.08%
5D
-11.48%
$5.61
Act: -23.82%
20D
-5.84%
$5.97
Act: -19.87%
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.ce06d217.1784464114.b5b8ebb2
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
This page provides OptimizeRx Corporation (OPRX) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on OPRX's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.